In Stock Cell Lines
Homo sapiens (Human)
Brain (parietal lobe)
Adherent
This CRISPR/Cas9-edited NF1 knockout U-251MG cell line eliminates neurofibromin, a RAS GTPase-activating protein, causing sustained RAS-GTP loading and constitutive activation of the RAF-MEK-ERK and PI3K-AKT-mTOR pathways. Derived from a human glioblastoma cell line with PTEN mutation and EGFR amplification, the model recapitulates key oncogenic signaling features of NF1-deficient tumors. Applications encompass RAS pathway inhibitor screening, glioblastoma drug resistance studies, and functional genomics. Key readouts include RAS-GTP pull-down, phospho-ERK/AKT western blotting, and cell-based assays for proliferation, apoptosis, and migration. This knockout cell line serves as a defined platform for preclinical therapeutic evaluation.
COQ7 Knockout NCI-H1299 Polyclonal Cells
Cat. No. ARG17675
MND1 Knockout jurkat Polyclonal Cells
Cat. No. ARG13436
LGALSL Knockout Hela Polyclonal Cells
Cat. No. ARG8823
DMXL1 Knockout HAP1 Polyclonal Cells
Cat. No. ARG39009
CPPED1 Knockout MES-OV Polyclonal Cells
Cat. No. ARG6659
FOXA1 Knockout 22RV1 Cell Line
Cat. No. ARG0007
The NF1 Knockout U-251MG Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the human U-251MG glioblastoma cell line. This engineered model carries a targeted disruption of the NF1 tumor suppressor gene, resulting in loss of functional neurofibromin protein. It provides a defined loss-of-function system for investigating NF1-dependent signaling and its role in glioblastoma tumorigenesis.
The parental U-251MG line is a widely used human glioblastoma model of the aggressive mesenchymal subtype. It features wild-type TP53, a loss-of-function mutation in the PTEN tumor suppressor, and amplification of the EGFR gene. These genetic lesions drive constitutive PI3K-AKT-mTOR pathway activity and enhanced receptor tyrosine kinase signaling, establishing a clinically relevant background for studying cooperative oncogenic effects with NF1 loss.
Neurofibromin functions as a GTPase-activating protein (GAP) for RAS family GTPases, including HRAS, KRAS, and NRAS. It accelerates the hydrolysis of active RAS-GTP to inactive RAS-GDP, thereby negatively regulating downstream effectors. Loss of NF1 GAP activity results in sustained RAS-GTP loading, which constitutively activates the RAF-MEK-ERK (BRAF/RAF1 ?? MEK1/2 ?? ERK1/2) and PI3K-AKT-mTOR signaling cascades. Additionally, RAS-dependent RalGEF?CRalA/B and transcription factors ELK1 and c-FOS are aberrantly engaged. The SPRED1 adaptor protein facilitates neurofibromin recruitment to the plasma membrane, and cAMP-PKA signaling modulates its activity.
In the context of U-251MG cells, NF1 knockout combines with pre-existing PTEN loss and EGFR amplification to hyperactivate both the MAPK and PI3K pathways, recapitulating the molecular features of NF1-mutant gliomas. This multi-hit model is especially suited for dissecting signaling network rewiring, adaptive resistance, and feedback mechanisms. It also provides a platform for identification of synthetic lethal interactions and evaluation of rational combination therapies targeting these oncogenic hubs.
This cell line supports a wide range of functional and pharmacological studies. Typical applications include dose-response screening of MEK inhibitors (such as trametinib) or PI3K/mTOR inhibitors, either alone or in combination. Cellular outcomes can be assessed via proliferation (MTT, BrdU, colony formation), apoptosis (Annexin V/PI staining), and migration/invasion (Transwell assays). Pathway activity is measurable through RAS-GTP pull-downs and western blotting for phospho-ERK1/2 and phospho-AKT. Gene expression changes can be quantified by RT-qPCR, and high-content assays such as phospho-kinase arrays are also compatible. The NF1 Knockout U-251MG Cell Line is a robust resource for glioblastoma research and therapeutic discovery. For technical inquiries and product information, please contact Ascent Research.
